Royce & Associates LP Acquires New Shares in Delcath Systems, Inc. $DCTH

Royce & Associates LP acquired a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 155,000 shares of the company’s stock, valued at approximately $1,566,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. California State Teachers Retirement System bought a new stake in shares of Delcath Systems during the 2nd quarter valued at $26,000. Russell Investments Group Ltd. purchased a new position in Delcath Systems during the third quarter worth about $29,000. Tower Research Capital LLC TRC purchased a new position in Delcath Systems during the second quarter worth about $40,000. Legal & General Group Plc purchased a new position in Delcath Systems during the second quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Delcath Systems during the second quarter worth about $151,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Trading Down 1.6%

DCTH opened at $10.78 on Friday. The stock has a 50-day moving average price of $10.45 and a 200-day moving average price of $9.96. Delcath Systems, Inc. has a 12-month low of $8.12 and a 12-month high of $17.35. The stock has a market capitalization of $372.13 million, a P/E ratio of 1,078.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The firm had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. On average, equities research analysts predict that Delcath Systems, Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

DCTH has been the subject of several recent analyst reports. Zacks Research cut Delcath Systems from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. BTIG Research reduced their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Evercore set a $27.00 target price on Delcath Systems in a research report on Thursday, February 26th. Finally, Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.50.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.